Completed PHASE1 INTERVENTIONAL 4-arm NCT01533116

Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide

Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy Subjects

Sponsor: Bial - Portela C S.A.

Conditions Parkinson Disease

Interventions BIA 9-1067 Placebo levodopa/benserazide levodopa/carbidopa

Updated 8 times since 2017 Last updated: Oct 14, 2015 Started: Mar 31, 2009 Primary completion: Aug 31, 2009 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01533116, this PHASE1 trial focuses on Parkinson Disease and remains completed. Sponsored by Bial - Portela C S.A., it has been updated 8 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bial - Portela C S.A.

Data source: Bial - Portela C S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mount Royal, Canada